Patents by Inventor David C. Remy

David C. Remy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazole compounds and their use as transglutaminase inhibitors
    Patent number: 5084444
    Abstract: Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: June 10, 1991
    Date of Patent: January 28, 1992
    Assignee: Merck & Co. Inc.
    Inventors: David A. Claremon, John J. Baldwin, David C. Remy
  • Imidazole compounds and their use as transglutaminase inhibitors
    Patent number: 5077285
    Abstract: Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: December 31, 1991
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, David C. Remy, John J. Baldwin
  • Triazole compounds and their use as transglutaminase inhibitors
    Patent number: 5047416
    Abstract: Azole compounds including azoles and azolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: September 10, 1991
    Assignee: Merck & Co., Inc.
    Inventors: David C. Remy, John J. Baldwin, David A. Claremon, Stella W. King
  • Class III antiarrhythmic agents
    Patent number: 5032604
    Abstract: Compounds of structural formula: ##STR1## wherein R' is hydrogen or an aromatic ring system, and Q is a substituted nitrogen or a nitrogen containing heterocycle, and E is --S-- or --O--, are Class III antiarrhythmic agents.
    Type: Grant
    Filed: December 8, 1989
    Date of Patent: July 16, 1991
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Gerald S. Ponticello, David C. Remy, Harold G. Selnick
  • Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
    Patent number: 5032598
    Abstract: Compounds of structural formula: ##STR1## wherein Ar is an aromatic ring, B is a cyclic moiety fused to Ar of 5-7 members and Q is a nitrogen containing heterocycle, are antiarrhythmic agents.
    Type: Grant
    Filed: December 8, 1989
    Date of Patent: July 16, 1991
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Gerald S. Ponticello, David C. Remy, Harold G. Selnick
  • Imidazole compounds and their use as transglutaminase inhibitors
    Patent number: 5030644
    Abstract: Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: July 9, 1991
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy, David A. Claremon
  • Method of traeting malaria with cyproheptadine derivatives
    Patent number: 5021426
    Abstract: Various 3-substituted cyproheptadine derivatives are useful in the treatment of infection by Plasmodium falciparum and in the treatment of malaria either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with antimalarial agents or compounds. Methods of treating malaria and methods of treating infection by Plasmodium falciparum are also described.
    Type: Grant
    Filed: February 26, 1990
    Date of Patent: June 4, 1991
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gabriel F. Eilon, Paul A. Friedman, David C. Remy
  • Imidazole compounds and their use as transglutaminase inhibitors
    Patent number: 5021440
    Abstract: Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: June 4, 1991
    Assignee: Merck & Co., Inc.
    Inventors: David C. Remy, John J. Baldwin, David A. Claremon, Stella W. King
  • Imidazole compounds and their use as transglutaminase inhibitors
    Patent number: 5019572
    Abstract: Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: February 7, 1990
    Date of Patent: May 28, 1991
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, John J. Baldwin, David C. Remy
  • Dibenzo[a,d]cycloheptenylidene compounds
    Patent number: 4996321
    Abstract: Various cyproheptadine derivatives sensitize multidrug resistant cells to certain chemotherapeutic agents. As such, these cyproheptadine derivatives are useful as adjuncts in the reversal of multidrug resistance in mammalian tumor cells either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with anticancer chemotherapeutic agents or compounds.
    Type: Grant
    Filed: February 26, 1990
    Date of Patent: February 26, 1991
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy
  • Certain imidazole compounds as transglutaminase inhibitors
    Patent number: 4968713
    Abstract: A method for inhibiting transglutaminase activity, especially Factor XIIIa activity with certain imidazole compounds is described. The imidazole compounds are those selected from(A) a imidazole having the formula ##STR1## or its acid addition salt, and ##STR2## wherein: R is hydrogen or lower alkyl;R.sup.1 is lower alkyl;R.sup.2 and R.sup.3 are independently hydrogen or lower alkyl;R.sup.4 is lower alkyl; andX is the negative radical of a pharmaceutically acceptable salt.Also described are compositions suitable for use in inhibiting transglutaminase activity.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: November 6, 1990
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy, David A. Claremon
  • Methods and compositions for thrombolytic therapy
    Patent number: 4968494
    Abstract: Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.
    Type: Grant
    Filed: April 10, 1990
    Date of Patent: November 6, 1990
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, Paul A. Friedman, David C. Remy, Andrew M. Stern
  • Oculoselective beta-blockers
    Patent number: 4945182
    Abstract: Hydroxyalkyl-phenoxy-propan-2-ol-3-amines are oculoselective .beta.-blockers useful in the treatment of elevated intraocular pressure with little or no effect on the pulmonary or cardiovascular system.
    Type: Grant
    Filed: September 29, 1986
    Date of Patent: July 31, 1990
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy, David A. Claremon
  • Amino-2-hydroxypropyloximinoheterocycle .alpha.-blockers
    Patent number: 4803286
    Abstract: Certain amino-2-hydroxypropyloximinoheterocycles are .beta.-adrenoceptor antagonists useful in the treatment of elevated intraocular pressure, hypertension, angina and arrhythmia.
    Type: Grant
    Filed: August 19, 1987
    Date of Patent: February 7, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello, David C. Remy, David A. Claremon, Stella W. King
  • Benzocycloheptapyridone compounds for treating congestive heart failure
    Patent number: 4639457
    Abstract: Novel benzocycloheptapyridone compounds are disclosed. The compounds exhibit inotropic potencies and are adaptable to being utilized as cardiotonic agents in the chemotherapeutic treatment of cardiovascular diseases.
    Type: Grant
    Filed: August 19, 1985
    Date of Patent: January 27, 1987
    Assignee: Merck & Co., Inc.
    Inventor: David C. Remy
  • 4-(5H-dibenzo[a,d]cyclohepten-5-yl)piperidine compounds, pharmaceutical compositions and methods
    Patent number: 4626542
    Abstract: Pharmaceutical compositions comprising 4-(5H-dibenzo[a,d]cyclohepten-5-yl)piperidine compounds and the use of 4-(5H-dibenzo[a,d]cyclohepten-5-yl)piperidine compounds for treatment of certain cardiovascular disorders are disclosed.
    Type: Grant
    Filed: April 5, 1984
    Date of Patent: December 2, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Stella W. King, David C. Remy
  • Pharmaceutical compositions of 4-(dibenzo-[a,d]cycloalkenyl)piperazine compounds and methods
    Patent number: 4616023
    Abstract: Pharmaceutical compositions comprising 4-(dibenzo[a,d]cycloalkenyl)piperazine compounds and the use of said piperazine compounds for treatment of certain cardiovascular disorders are disclosed.
    Type: Grant
    Filed: February 21, 1985
    Date of Patent: October 7, 1986
    Assignee: Merck & Co., Inc.
    Inventors: David C. Remy, Steven D. Young
  • Indeno[2,1-c]pyridine compounds, and their use as calcium channel blockers
    Patent number: 4605660
    Abstract: Indeno[2,1-c]pyridine compounds, particularly cyano substituted tetrahydroindeno[2,1-c]pyridine dicarboxylic acid ester compounds, their preparation and their use as calcium entry blockers are disclosed.
    Type: Grant
    Filed: June 3, 1985
    Date of Patent: August 12, 1986
    Assignee: Merck & Co., Inc.
    Inventor: David C. Remy
  • Cyclopropyl pyridine compounds useful as calcium channel blockers
    Patent number: 4591587
    Abstract: Novel cyclopropyl pyridine compounds useful as calcium channel blockers, pharmaceutical compositions thereof, and methods of treatment are disclosed.
    Type: Grant
    Filed: October 1, 1984
    Date of Patent: May 27, 1986
    Assignee: Merck & Co., Inc.
    Inventor: David C. Remy
  • N-(2-imidazolidinylidene)-5H-dibenzo[a,d]cyclohepten-5-amine compounds and .alpha..sub.2 -adrenergic antagonistic uses thereof
    Patent number: 4590202
    Abstract: N-(2-Imidazolidinylidene)-5H-dibenzo[a,d]cyclohepten-5-amine compounds are disclosed. The compounds have the property of inhibiting calcium induced contraction of smooth muscle. Certain of the compounds have properties of .alpha..sub.2 -adrenergic antagonists and others of .alpha..sub.2 -adrenergic agonists.
    Type: Grant
    Filed: January 19, 1984
    Date of Patent: May 20, 1986
    Assignee: Merck & Co., Inc.
    Inventor: David C. Remy